{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:26:41Z","timestamp":1759541201392,"version":"3.41.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.7759\/cureus.89042","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:23:42Z","timestamp":1753867422000},"source":"Crossref","is-referenced-by-count":1,"title":["Late-Onset Angioimmunoblastic T-cell Lymphoma During Nivolumab Treatment for Melanoma"],"prefix":"10.7759","author":[{"given":"Akihiro","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Murao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruya","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain M","year":"2024","unstructured":"Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024, 143:113365. 10.1016\/j.intimp.2024.113365","journal-title":"Int Immunopharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1292122","article-title":"Achilles' heel of currently approved immune checkpoint inhibitors: immune related adverse events","volume":"15","author":"Yan T","year":"2024","unstructured":"Yan T, Yu L, Zhang J, Chen Y, Fu Y, Tang J, Liao D. Achilles' heel of currently approved immune checkpoint inhibitors: immune related adverse events. Front Immunol. 2024, 15:1292122. 10.3389\/fimmu.2024.1292122","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.804597","article-title":"Holistic approach to immune checkpoint inhibitor-related adverse events","volume":"13","author":"Poto R","year":"2022","unstructured":"Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, Varricchi G. Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol. 2022, 13:804597. 10.3389\/fimmu.2022.804597","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy","volume":"8","author":"Anand K","year":"2020","unstructured":"Anand K, Ensor J, Pingali SR, et al.. T-cell lymphoma secondary to checkpoint inhibitor therapy. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000104","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17144","article-title":"Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor","volume":"8","author":"Guo L","year":"2017","unstructured":"Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017, 8:410-6. 10.7150\/jca.17144","journal-title":"J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang SQ","year":"2021","unstructured":"Tang SQ, Tang LL, Mao YP, et al.. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat. 2021, 53:339-54. 10.4143\/crt.2020.790","journal-title":"Cancer Res Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.12.008","article-title":"Cholangitis induced by immune checkpoint inhibitors: analysis of pharmacovigilance data","volume":"22","author":"Meunier L","year":"2024","unstructured":"Meunier L, Hountondji L, Jantzem H, Faillie JL, Maria A, Palassin P. Cholangitis induced by immune checkpoint inhibitors: analysis of pharmacovigilance data. Clin Gastroenterol Hepatol. 2024, 22:1542-1545.e4. 10.1016\/j.cgh.2023.12.008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1508512","article-title":"Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"16","author":"Fang Q","year":"2025","unstructured":"Fang Q, Qian Y, Xie Z, Zhao H, Zheng Y, Li D. Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis. Front Immunol. 2025, 16:1508512. 10.3389\/fimmu.2025.1508512","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella LV","year":"2012","unstructured":"Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant. 2012, 12:2575-87. 10.1111\/j.1600-6143.2012.04224.x","journal-title":"Am J Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.63.759","article-title":"Angioimmunoblastic T-cell lymphoma after immune checkpoint inhibitor-combined chemotherapy for lung cancer (Article in Japanese)","volume":"63","author":"Kawakami A","year":"2022","unstructured":"Kawakami A, Kuroda H, Suzuki T, et al.. Angioimmunoblastic T-cell lymphoma after immune checkpoint inhibitor-combined chemotherapy for lung cancer (Article in Japanese). Rinsho Ketsueki. 2022, 63:759-63. 10.11406\/rinketsu.63.759","journal-title":"Rinsho Ketsueki"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.66974","article-title":"Development of subcutaneous panniculitis-like T-cell lymphoma after immune checkpoint inhibitor treatment","volume":"16","author":"Yu TY","year":"2024","unstructured":"Yu TY, Gul Z, Hunt AM, Williams MJ, Maley AM. Development of subcutaneous panniculitis-like T-cell lymphoma after immune checkpoint inhibitor treatment. Cureus. 2024, 16:e66974. 10.7759\/cureus.66974","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5070\/D328157071","article-title":"Cutaneous T-cell lymphoma developing during nivolumab treatment for metastatic melanoma","volume":"28","author":"Hida Y","year":"2022","unstructured":"Hida Y, Kageji R, Bekku H, Watanabe S, Seike T, Yamashita M. Cutaneous T-cell lymphoma developing during nivolumab treatment for metastatic melanoma. Dermatol Online J. 2022, 28:10.5070\/D328157071","journal-title":"Dermatol Online J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.12.033","article-title":"Nivolumab-associated cutaneous T-cell lymphoma","volume":"9","author":"Marks JA","year":"2021","unstructured":"Marks JA, Parker DC, Garrot LC, Lechowicz MJ. Nivolumab-associated cutaneous T-cell lymphoma. JAAD Case Rep. 2021, 9:39-41. 10.1016\/j.jdcr.2020.12.033","journal-title":"JAAD Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.09.020","article-title":"Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment","volume":"6","author":"Duke TC","year":"2020","unstructured":"Duke TC, Nair R, Torres-Cabala C, et al.. Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Rep. 2020, 6:1264-7. 10.1016\/j.jdcr.2020.09.020","journal-title":"JAAD Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.01.016","article-title":"Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma","volume":"4","author":"Zheng YJ","year":"2018","unstructured":"Zheng YJ, Lee A, Pincus L, Ho W, Vujic M, Ortiz-Urda S. Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Rep. 2018, 4:540-2. 10.1016\/j.jdcr.2018.01.016","journal-title":"JAAD Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3406-6","article-title":"\u03b3\u03b4 T cell clonal proliferation early after PD-1 blockade","volume":"98","author":"Ono K","year":"2019","unstructured":"Ono K, Onishi Y, Kobayashi M, et al.. \u03b3\u03b4 T cell clonal proliferation early after PD-1 blockade. Ann Hematol. 2019, 98:219-20. 10.1007\/s00277-018-3406-6","journal-title":"Ann Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13966","article-title":"CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: a case report","volume":"12","author":"Koda K","year":"2021","unstructured":"Koda K, Toyoshima M, Yazawa S, Fukada A, Sugimura H, Suda T. CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: a case report. Thorac Cancer. 2021, 12:1765-9. 10.1111\/1759-7714.13966","journal-title":"Thorac Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2215424","article-title":"Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors","volume":"16","author":"Ohmoto A","year":"2023","unstructured":"Ohmoto A, Fuji S. Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors. Expert Rev Hematol. 2023, 16:535-41. 10.1080\/17474086.2023.2215424","journal-title":"Expert Rev Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921445117","article-title":"Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy","volume":"117","author":"Wang X","year":"2020","unstructured":"Wang X, Yang X, Zhang C, et al.. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci U S A. 2020, 117:6640-50. 10.1073\/pnas.1921445117","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/385411-late-onset-angioimmunoblastic-t-cell-lymphoma-during-nivolumab-treatment-for-melanoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:23:43Z","timestamp":1753867423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/385411-late-onset-angioimmunoblastic-t-cell-lymphoma-during-nivolumab-treatment-for-melanoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.89042","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}